# Gate Bioscience

> Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.

## Why it is interesting

Gate Bioscience's differentiated protein-secretion blockade attracted ARCH and a16z across a $60M Series A and $65M Series B.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (2023): $60M co-led by Versant Ventures and a16z Bio + Health (/fund/andreessen-horowitz) with ARCH Venture Partners (/fund/arch-venture-partners) (BioCentury)
- Series B (2025): $65M with ARCH among existing investors (Gate Bio press)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

---
Source: https://venturecapitaltracker.com/startup/gate-bioscience